重组人干扰素α-1b和利巴韦林治疗儿童手足口病疗效对比研究  

Comparative Study on the Treatments for Hand- foot-mouth Disease in Children with Human Recombinant Interferon alph-1b and Ribavirin Respectively

作　　者：易俊[1] 

机构地区：[1]大理学院大理教学医院,云南大理671000

出　　处：《大理学院学报（综合版）》2014年第4期41-43,共3页Journal of Dali University

摘　　要：目的：探讨重组人干扰素α-1b治疗儿童手足口病的疗效和安全性。方法：将388例手足口病患儿随机分为两组,两组患儿给予相同的对症和支持治疗。治疗组184例用重组人干扰素α-1b肌肉注射,〈1岁1 ug/（kg·d）,2-10岁10 ug/d,1次/d;对照组204例用利巴韦林〔10-15 mg/（kg·d）〕静脉滴注。结果：治疗组与对照组比较,在退热时间,手足皮疹及口腔溃疡愈合方面均优于对照组（P〈0.01）,除个别患儿有发热外,治疗组未发现明显副作用。结论：干扰素治疗儿童手足口病安全有效,值得临床推广使用。Objective：To discuss the effect and safety of the treatment for children＇s hand- foot-mouth disease with human recombinantinterferon alph-1b. Methods：388 cases of children with hand-foot-mouth disease were randomly divided into two groups which were given the same support and symptomatic treatment. Treatment group,184 cases were treated with human recombinant interferon alph-1b, 1,1 ug（kg·d）,intramuscular,2-10 10 ug/d muscle injection,1 times a day. The control group, 204 cases were treated with ribavirin〔10-15 mg /（kg·d）〕an intravenous drip. Results：The treatment group was better than control group（P〈0.01） in the defervescence time,hand,foot and skin rash and mouth ulcer healing. In addition to that the individual children have a fever;there was no obvious side effect in the treatment group. Conclusion：Interferon treatment of hand,foot and mouth disease in children is safe and effective,and is worth popularizing clinically used.

关 键 词：干扰素 利巴韦林 手足口病 儿童 

分 类 号：R512.5[医药卫生—内科学]